NO20035025L - Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. - Google Patents

Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.

Info

Publication number
NO20035025L
NO20035025L NO20035025A NO20035025A NO20035025L NO 20035025 L NO20035025 L NO 20035025L NO 20035025 A NO20035025 A NO 20035025A NO 20035025 A NO20035025 A NO 20035025A NO 20035025 L NO20035025 L NO 20035025L
Authority
NO
Norway
Prior art keywords
osteopontin
prevention
treatment
antagonist
activity
Prior art date
Application number
NO20035025A
Other languages
English (en)
Norwegian (no)
Other versions
NO20035025D0 (no
Inventor
Ursula Boschert
Georg Feger
Raghuram Selvaraju
Ruben Papoian
Lilia Bernasconi
Original Assignee
Merck Serono As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono As filed Critical Merck Serono As
Publication of NO20035025L publication Critical patent/NO20035025L/no
Publication of NO20035025D0 publication Critical patent/NO20035025D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
NO20035025A 2001-05-17 2003-11-12 Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer NO20035025D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111296 2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en) 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (2)

Publication Number Publication Date
NO20035025L true NO20035025L (no) 2003-11-12
NO20035025D0 NO20035025D0 (no) 2003-11-12

Family

ID=8177366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035025A NO20035025D0 (no) 2001-05-17 2003-11-12 Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer

Country Status (27)

Country Link
US (4) US7217687B2 (ru)
EP (1) EP1389130B1 (ru)
JP (2) JP4417632B2 (ru)
KR (1) KR100947424B1 (ru)
CN (2) CN1939538A (ru)
AT (1) ATE555803T1 (ru)
AU (1) AU2002312886B2 (ru)
BG (1) BG108337A (ru)
BR (1) BR0209812A (ru)
CA (1) CA2443964A1 (ru)
CZ (1) CZ20033109A3 (ru)
EA (1) EA006655B1 (ru)
EE (1) EE200300559A (ru)
ES (1) ES2387082T3 (ru)
HK (1) HK1067051A1 (ru)
HR (1) HRP20030840A2 (ru)
HU (1) HUP0400005A3 (ru)
IL (2) IL158867A0 (ru)
MX (1) MXPA03010327A (ru)
NO (1) NO20035025D0 (ru)
NZ (1) NZ528852A (ru)
PL (1) PL211763B1 (ru)
SK (1) SK14232003A3 (ru)
UA (1) UA85368C2 (ru)
WO (1) WO2002092122A2 (ru)
YU (1) YU89503A (ru)
ZA (1) ZA200307956B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090974A2 (de) * 2001-05-09 2002-11-14 Biovision Ag Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
AU2002357748A1 (en) * 2001-11-21 2003-06-10 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
MXPA04012803A (es) * 2002-06-25 2005-06-08 Aventis Pharma Inc Osteopontina, oligodendrocitos y mielinizacion.
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
AU2004224779A1 (en) * 2003-03-28 2004-10-07 Laboratoires Serono Sa Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
NZ546398A (en) * 2003-09-18 2009-03-31 Arla Foods Amba Infant formula
AU2004288654B2 (en) * 2003-11-12 2009-12-03 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US20060264371A1 (en) * 2005-02-18 2006-11-23 Proximagen Ltd. Treatment
ATE485831T1 (de) * 2005-02-18 2010-11-15 Proximagen Ltd Behandlung von neurodegeneration
ZA200803929B (en) 2005-10-13 2009-08-26 Anthrogenesis Corp Production of oligodendrocytes from placenta-derived stem cells
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) * 2008-09-16 2010-03-18 Laree Hiser Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko) * 2011-04-21 2014-10-13 가톨릭대학교 산학협력단 신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
WO2014051398A1 (ko) * 2012-09-28 2014-04-03 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
WO2016033329A1 (en) * 2014-08-27 2016-03-03 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
JP2019519515A (ja) 2016-05-20 2019-07-11 シーダーズ—シナイ メディカル センター アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法
EP3544994B1 (en) * 2016-11-27 2024-09-25 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from microalgae
WO2018202870A1 (en) 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes
US11484576B2 (en) 2017-08-15 2022-11-01 The Children's Medical Center Corporation Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment
TR201903865A2 (tr) * 2019-03-14 2020-09-21 Bogazici Ueniversitesi Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) * 2019-08-08 2021-02-11 Ramot At Tel-Aviv University Ltd. Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
WO2021246744A1 (ko) * 2020-06-02 2021-12-09 가톨릭대학교 산학협력단 오스테오폰틴 억제제를 유효성분으로 포함하는 퇴행성 신경계질환의 예방, 개선 또는 치료용 조성물
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579871A1 (en) * 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
EP1175223A2 (en) 1999-04-15 2002-01-30 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2000064460A2 (en) * 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
AU782298B2 (en) * 1999-10-04 2005-07-14 Nektar Therapeutics Polymer stabilized neuropeptides

Also Published As

Publication number Publication date
AU2002312886B2 (en) 2007-10-25
WO2002092122A2 (en) 2002-11-21
WO2002092122A3 (en) 2003-03-06
SK14232003A3 (sk) 2004-05-04
PL367065A1 (en) 2005-02-21
MXPA03010327A (es) 2004-02-17
PL211763B1 (pl) 2012-06-29
CA2443964A1 (en) 2002-11-21
CN1286524C (zh) 2006-11-29
EP1389130A2 (en) 2004-02-18
HRP20030840A2 (en) 2005-08-31
JP4417632B2 (ja) 2010-02-17
EP1389130B1 (en) 2012-05-02
HUP0400005A3 (en) 2012-09-28
US20080213234A1 (en) 2008-09-04
NZ528852A (en) 2005-12-23
YU89503A (sh) 2006-05-25
JP2009191082A (ja) 2009-08-27
CZ20033109A3 (en) 2004-06-16
JP5036761B2 (ja) 2012-09-26
US20040235720A1 (en) 2004-11-25
UA85368C2 (ru) 2009-01-26
EE200300559A (et) 2004-02-16
EA006655B1 (ru) 2006-02-24
ATE555803T1 (de) 2012-05-15
CN1939538A (zh) 2007-04-04
HK1067051A1 (en) 2005-04-01
KR100947424B1 (ko) 2010-03-12
US20070225214A1 (en) 2007-09-27
EA200301253A1 (ru) 2004-06-24
IL158867A (en) 2010-05-17
ZA200307956B (en) 2004-10-13
BG108337A (bg) 2004-12-30
BR0209812A (pt) 2004-06-01
US20050176639A1 (en) 2005-08-11
IL158867A0 (en) 2004-05-12
ES2387082T3 (es) 2012-09-13
JP2004536058A (ja) 2004-12-02
US7297099B2 (en) 2007-11-20
KR20040008176A (ko) 2004-01-28
US7217687B2 (en) 2007-05-15
NO20035025D0 (no) 2003-11-12
CN1533283A (zh) 2004-09-29
HUP0400005A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006002437A3 (en) Treatment of conditions involving demyelination
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2003080582A3 (de) Fredericamycin-derivate
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2005123113A3 (en) Interferon compositions and methods of use thereof
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
UA85187C2 (en) 2-aminobenzoyl derivatives
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application